
Please try another search
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Elena H. Ridloff | 44 | 2021 | Independent Director |
Bruce L. Booth | 51 | 2015 | Co-Founder & Independent Chairman |
Nello Mainolfi | 46 | 2017 | Co-Founder, President, CEO & Director |
Jeffrey W. Albers | 54 | 2020 | Independent Director |
Pamela Esposito | 50 | 2020 | Independent Director |
Victor Sandor | 59 | 2022 | Independent Director |
John M. Maraganore | 63 | 2022 | Independent Director |
Gorjan Hrustanovic | 36 | 2020 | Independent Director |
Felix James Baker | 56 | 2024 | Lead Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review